20 articles
Flaxseed compounds enhance PD-1 inhibitor effectiveness against breast cancer through gut bacteria modulation and immune system activation.
Researchers propose a unified model classifying cancer-associated fibroblasts by molecular phenotype and spatial location to guide precision therapy.
A completed exploratory trial evaluates whether a specialized compression garment can reduce discomfort and improve quality of life in pelvic lymphedema patients.
A clinical trial shows 4g/day icosapent ethyl nearly tripled marine omega-3 content in colorectal tissue, shifting the omega-3/omega-6 ratio favorably.
Researchers developed rat and mouse models mimicking early and middle stages of oral submucous fibrosis using bleomycin injections.
Ginsenoside Rh4 suppresses colorectal cancer by boosting Akkermansia muciniphila and elevating protective bile acid UDCA via FXR signaling.
Engineered magnetotactic bacteria delivered orally penetrate colorectal tumors, trigger immune attack, and reshape gut microbial metabolism in mice.
A growth factor called GDF11 reprograms pro-tumor macrophages by rewiring their metabolism, suppressing hepatocellular carcinoma growth.
Specific gut microbes produce compounds that reprogram fat cells to enhance immune responses against cancer.
New research reveals how successful chemotherapy creates special cells that enhance immune response and restrain tumor growth.
Researchers discovered why fibrolamellar carcinoma resists immunotherapy and found an existing drug can free trapped T cells to fight it.
Retrospective study of 120 NSCLC patients finds thymalfasin plus chemoimmunotherapy significantly extends PFS and OS without added toxicity.
Researchers find that combining Ganoderma lucidum and Sanghuangporus vaninii extracts may fight colorectal cancer through vitamin D and Wnt pathways.
Peter Attia explains the science behind fasting as a tool to enhance chemotherapy efficacy while protecting healthy cells.
Spatial multi-omics reveals how specific fibroblasts create immunosuppressive environments that fuel colorectal cancer spread to the liver.
Comprehensive review reveals promising new drug targets and immunotherapy approaches for myelofibrosis beyond current JAK inhibitor limitations.
Fibrotic tissue stiffness activates a cascade that recruits immune cells and generates DNA-damaging aldehydes, linking dense breast tissue to cancer risk.
Tissue stiffness triggers a chain reaction — recruiting macrophages that generate DNA-damaging lipid byproducts — linking fibrosis directly to cancer initiation.
Scientists discover how two microbes team up to accelerate colon cancer, but L-arginine may disrupt their deadly partnership.
Massive spatial analysis reveals conserved fibroblast subtypes that control immune infiltration and therapy response across cancer types.
